Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis

Completed · Phase 3 · Has a placebo group

Conditions studied: End Stage Renal Disease, Chronic Kidney Disease

In brief

The purpose of the parent study is to assess the short-term safety and tolerability of soluble ferric pyrophosphate (SFP) in dialysate administered to a large number of representative adult chronic kidney disease patients on hemodialysis (CKD-HD). The purpose of the extension study is to assess the long-term safety and tolerability of SFP.

Key facts

Study ID
NCT01503021
Run by
Rockwell Medical Technologies, Inc.
People needed
718
Starts
2011-11-01
Expected to finish
2014-01-01
Last updated by the study team
2016-10-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.